Veyvondi
What Veyvondi is used for
Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Veyvondi
- Active substance
- vonicog alfa
- Disease area
- von Willebrand Diseases
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD10
- Marketing authorisation holder
- Baxalta Innovations GmbH
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Veyvondi used for?
Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
What is the active substance in Veyvondi?
Veyvondi contains vonicog alfa.
Who makes Veyvondi?
The EU marketing authorisation holder is Baxalta Innovations GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU